Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Bullish +65

Bristol-Myers Squibb stock gains on positive Sotyktu data and solid Q2 figures

AI-generated analysis

📈 Bristol-Myers Squibb reported Q2 2026 revenue of USD 12.97 billion, representing a 6 percent year-over-year increase driven by the Growth Portfolio.

💊 Positive two-year data for Sotyktu in psoriatic arthritis from the POETYK PsA-2 study highlights durable efficacy and a favorable safety profile.

📉 The Legacy Portfolio declined 4 percent to USD 5.42 billion due to continued generic erosion affecting oncology drugs Revlimid and Pomalyst.

💰 Bristol-Myers Squibb maintained its quarterly dividend at USD 0.63 per share, providing a yield of approximately 3.95 percent to shareholders.

🎯 Non-GAAP EPS for Q2 2026 reached USD 2.04, significantly beating the consensus estimate of USD 1.60 and demonstrating strong profitability.

📊 Eliquis revenue within the Legacy Portfolio grew 22 percent to USD 4.48 billion, offsetting declines in other oncology segments.

👥 Analysts maintain a Moderate Buy rating with an average target price of USD 66.71, suggesting potential upside from current levels.

⚠️ Generic competition facing Revlimid and Pomalyst remains a key risk that could continue to weigh on the Legacy Portfolio's performance.

Bullish Signals
  • Bristol-Myers Squibb reported Q2 2026 revenue of USD 12.97 billion, a 6 percent year-over-year increase driven by strong growth in its Growth Portfolio.
  • Non-GAAP EPS for the quarter reached USD 2.04, significantly beating the consensus estimate of USD 1.60 and demonstrating robust profitability.
  • Positive two-year clinical trial data for Sotyktu in psoriatic arthritis demonstrated durable efficacy and a consistent safety profile, serving as a new catalyst.
  • Eliquis revenue within the Legacy Portfolio grew 22 percent to USD 4.48 billion, highlighting the strength of the cardiovascular franchise.
  • The company maintained its quarterly dividend at USD 0.63 per share with a sustainable payout ratio of 39 percent and a three-year growth rate of 4.4 percent.
Risk Factors
  • The Legacy Portfolio declined 4 percent to USD 5.42 billion due to ongoing generic erosion affecting oncology assets Revlimid and Pomalyst.
  • Valuation analysis suggests the stock trades approximately 12.4 percent above its GF Value estimate, which could limit near-term upside if earnings growth slows.
Full Analysis
Bristol-Myers Squibb (BMY) shares gained momentum following the release of positive two-year clinical trial data for its immunology drug Sotyktu in psoriatic arthritis. The Phase 3 POETYK PsA-2 study and its open-label extension demonstrated durable efficacy and a consistent safety profile, with results presented at the Congress of Clinical Rheumatology - West. This development serves as a new catalyst for the company's efforts to expand Sotyktu beyond its existing indications in plaque psoriasis. Fundamentally, Bristol-Myers Squibb reported robust second-quarter 2026 financial results that exceeded market expectations. Revenue rose 6 percent year-over-year to USD 12.97 billion, while non-GAAP earnings per share (EPS) increased to USD 2.04, beating the consensus estimate of USD 1.60 by a significant margin. The Growth Portfolio drove this expansion with a 15 percent revenue increase, whereas the Legacy Portfolio declined 4 percent due to generic erosion in oncology assets like Revlimid and Pomalyst. The company maintains a sustainable capital return profile with a quarterly dividend of USD 0.63 per share, offering a yield of approximately 3.95 percent. Analyst consensus rates BMY as a Moderate Buy with an average target price near USD 66.71, implying upside potential from the recent trading levels around USD 63.60. However, investors must monitor ongoing generic competition pressures and valuation metrics that suggest the stock trades slightly above its intrinsic value estimate.